Prevalence of Homebound 22 Percent in National Medicare Advantage Plan

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

MONDAY, Aug. 12, 2024 -- In a national Medicare Advantage (MA) plan, the prevalence of homebound is 22 percent, and homebound status is independently associated with increased health service use and mortality, according to a study published online Aug. 13 in the Annals of Internal Medicine.

Bruce Leff, M.D., from the Johns Hopkins University School of Medicine in Baltimore, and colleagues examined the prevalence, characteristics, predictors, health service use, and mortality outcomes of homebound beneficiaries of a national MA plan (2,435,519 Humana MA beneficiaries) in 2022. Homebound status was assessed via in-home assessment and categorized as homebound, semi-homebound, and not homebound.

The researchers found that the overall prevalence of homebound beneficiaries was 22.0 percent in 2022 (8.4 percent homebound; 13.6 percent semi-homebound). Homebound status was predicted by female sex, low-income status or dual eligibility for Medicaid and Medicare, dementia, and moderate-to-severe frailty in adjusted models (odds ratios, 1.36, 1.56, 2.36, and 4.32, respectively). Increased odds of any emergency department visit, any inpatient hospital admission, any skilled nursing-facility admission, and death were seen in association with homebound status in a multivariable logistic regression (odds ratios, 1.14, 1.44, 2.18, and 2.55, respectively).

"In the context of MA, homebound persons should be of special interest because frail older adults account for more than half of all preventable costs among Medicare beneficiaries," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-08-13 07:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords